Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Tumor Immunotherapy01:27

Tumor Immunotherapy

596
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
596
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

1.0K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Cancer Vaccines01:30

Cancer Vaccines

456
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
456

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial.

Nature communications·2026
Same author

Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis.

The oncologist·2026
Same author

Fangchinoline derivative LYY-34 suppresses TNBC by inhibiting BLM DNA helicase from unfolding of c-MYC promoter G-quadruplex DNA.

Biochemical pharmacology·2026
Same author

Correction: Navigating drug-drug interactions with apalutamide.

Prostate cancer and prostatic diseases·2026
Same author

The path forward for T cell engagers in patients with prostate cancer.

Journal for immunotherapy of cancer·2026

Video Experimental Relacionado

Updated: Aug 2, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K

Terapia de punto de control inmunológico: perspectivas actuales y direcciones futuras

Padmanee Sharma1, Sangeeta Goswami2, Deblina Raychaudhuri3

  • 1Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Cell
|April 14, 2023
PubMed
Resumen

La terapia de control inmunológico (TIC) ofrece beneficios duraderos para el cáncer, pero tiene tasas de respuesta variables. La comprensión de los factores inmunes y no inmunes es crucial para optimizar la selección de pacientes y mejorar la eficacia de las TIC.

Palabras clave:
CTLA-4 (en inglés)Las TICPD-1 y sus derivadosPD-L1 y sus derivadoslos biomarcadores combinatoriosProteína citotóxica asociada a los linfocitos T 4Terapia de punto de control inmunológicoreacciones adversas relacionadas con el sistema inmunológicoLos EEIproteína de muerte celular programada 1ligando de muerte programada 1Traducción al revés

Más Videos Relacionados

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

511
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

462

Videos de Experimentos Relacionados

Last Updated: Aug 2, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

511
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

462

Área de la Ciencia:

  • Inmunología
  • En el campo de la oncología
  • Tratamiento del cáncer

Sus antecedentes:

  • La terapia de control inmunológico (TIC) ha revolucionado el tratamiento del cáncer, proporcionando respuestas duraderas en algunos pacientes.
  • La variabilidad de las tasas de respuesta de las TIC en diferentes tipos de tumores requiere mejores estrategias de selección de pacientes.
  • La identificación de biomarcadores predictivos es esencial para maximizar la eficacia de las TIC y minimizar las toxicidades relacionadas con el tratamiento.

Objetivo del estudio:

  • Revisar los mecanismos biológicos de la inmunidad antitumoral que influyen en la respuesta y la resistencia a las TIC.
  • Discutir los desafíos actuales y los esfuerzos en curso para mejorar la eficacia de las TIC.
  • Esbozar estrategias para futuros ensayos clínicos y terapias combinadas que involucren las TIC.

Principales métodos:

  • Revisión de la literatura centrada en la inmunidad antitumoral.
  • Análisis de los factores que afectan la respuesta y la resistencia a los inhibidores del punto de control inmunológico.
  • Síntesis de datos para informar el desarrollo clínico futuro.

Principales resultados:

  • Exploración detallada de los factores inmunes y no inmunes que afectan a los resultados de las TIC.
  • Identificación de los principales desafíos que obstaculizan una aplicación más amplia de las TIC.
  • Estrategias propuestas para optimizar la selección de pacientes y las terapias combinadas.

Conclusiones:

  • Una comprensión completa de la inmunidad antitumoral es vital para el avance de las TIC.
  • Abordar las limitaciones actuales requiere un enfoque multifacético que incluya el descubrimiento de biomarcadores.
  • La investigación futura debe centrarse en estrategias combinatorias y diseños de ensayos clínicos refinados para mejorar los beneficios de las TIC.